Lianhuan Pharmaceutical announced that the 26th interim meeting of the 9th board of directors of the company reviewed and approved: Sun Company Sichuan Longyi Pharmaceutical Co., Ltd. intends to apply for a comprehensive credit line totaling not more than RMB 271 million from the date of board review and approval until the 2026 annual shareholders' meeting; the holding subsidiary Lianhuan Medical Technology Co., Ltd. plans to apply for a loan of RMB 10 million from the related party Jiangsu Lianhuan Health Industry Management and Development Co., Ltd., for a period not exceeding 3 months. The annual interest rate on the loan is 2.5%, and the maturity period is one-time debt repayment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.